---
title: "STRIDE trial analysis confirms potential impact of semaglutide on quality-of-life metrics for PAD patients with diabetes"
date: "2025-06-23T10:01:47.000Z"
publishedDate: "23 juin 2025"
summary: "The findings of a new analysis from the STRIDE trial, presented at the American Diabetes Association (ADA) 2025 scientific session (20–23 June, Chicago, USA) and published in Diabetes Care, demonstrate the potential vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including improvement in symptoms, quality of life, and [&#8230;] The post STRIDE trial analysis confirms potential impact of semaglutide on quality-of-life metrics for PAD patients with diabetes appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/stride-trial-analysis-confirms-potential-impact-of-semaglutide-on-quality-of-life-metrics-for-pad-patients-with-diabetes/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2025-06-23-stride-trial-analysis-confirms-potential-impact-of-semaglutide-on-quality-of-life-metrics-for-pad-patients-with-diabetes"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2021/01/Walking.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/stride-trial-analysis-confirms-potential-impact-of-semaglutide-on-quality-of-life-metrics-for-pad-patients-with-diabetes/"
---

![STRIDE trial analysis confirms potential impact of semaglutide on quality-of-life metrics for PAD patients with diabetes](https://vascularnews.com/wp-content/uploads/sites/7/2021/01/Walking.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/stride-trial-analysis-confirms-potential-impact-of-semaglutide-on-quality-of-life-metrics-for-pad-patients-with-diabetes/*

## L’essentiel

The findings of a new analysis from the STRIDE trial, presented at the American Diabetes Association (ADA) 2025 scientific session (20–23 June, Chicago, USA) and published in Diabetes Care, demonstrate the potential vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including improvement in symptoms, quality of life, and [&#8230;] The post STRIDE trial analysis confirms potential impact of semaglutide on quality-of-life metrics for PAD patients with diabetes appeared first on Vascular News .

## Lien source

https://vascularnews.com/stride-trial-analysis-confirms-potential-impact-of-semaglutide-on-quality-of-life-metrics-for-pad-patients-with-diabetes/
